

Supporting Information

Structure-based Optimization of Inhibitors of the Tyrosine Kinase EphB4. Part 2: Cellular Potency Improvement and Binding Mode Validation by X-ray Crystallography

Karine Lafleur,^{†,‡,#} Jing Dong,^{‡,#} Danzhi Huang,[‡] Amedeo Caflisch,^{*,‡} and Cristina Nevado^{*,†}

[†]*Department of Organic Chemistry and* [‡]*Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland*

Table of contents

- Title Page
- Table S1: Selectivity for compound **40**
- NCI-data on the anti-proliferative activity of compound **3**
- Experimental Section
- ¹H-NMR and ¹³C-NMR of selected compounds
- HPLC trace (for purity) of tested compounds
- Composite Omit Map of Ligand **3**

* To whom correspondence should be addressed. Phone: (41) 446353945. Fax: (41) 446353948.

E-mail: nevado@oci.uzh.ch, caflisch@bioc.uzh.ch

These two authors contributed equally to this work.

[†] Dept. of Organic Chemistry

[‡] Dept. of Biochemistry

* To whom correspondence should be addressed. Phone: (41) 446353945. Fax: (41) 446353948.

E-mail: nevado@oci.uzh.ch, caflisch@bioc.uzh.ch

These two authors contributed equally to this work.

[†] Dept. of Organic Chemistry

[‡] Dept. of Biochemistry

Table S1. Selectivity of compound **40** tested on a panel of 124 protein kinases at the University of Dundee. The percentage of kinase activity is measured in the presence of 3 μ M of **40** compared to a 100% DMSO control.

Kinase	% act.	Kinase	% act.	Kinase	% act.	Kinase	% act.	Kinase	% act.
MKK1	56	MNK1	105	CK1	97	MEKK1	112	EPH-B4	18
MKK2	86	MNK2	103	CK2	91	MLK1	106	FGF-R1	88
MKK6	105	MAPKAP-K2	99	TTBK1	97	MLK3	101	HER4	91
ERK1	96	MAPKAP-K3	70	DYRK1A	96	TESK1	84	IGF-1R	112
ERK2	105	PRAK	99	DYRK2	93	TAO1	107	IR	99
JNK1	96	CAMKKb	99	DYRK3	101	ASK1	111	IRR	111
JNK2	95	CAMK1	84	NEK2a	108	TAK1	107	TrkA	90
JNK3	87	SmMLCK	104	NEK6	90	IRAK1	118	VEG-FR	87
p38a MAPK	107	PHK	93	IKKb	80	IRAK4	97		
p38b MAPK	98	DAPK1	115	IKKe	93	RIPK2	12		
p38g MAPK	108	CHK1	108	TBK1	101	OSR1	104		
p38d MAPK	102	CHK2	107	PIM1	98	TTK	104		
ERK8	94	GSK3b	123	PIM2	96	MPSK1	83		
RSK1	98	CDK2-Cyclin A	114	PIM3	92	Src	2		
RSK2	84	PLK1	102	SRPK1	91	Lck	5		
PDK1	104	Aurora A	77	EF2K	97	CSK	57		
PKBa	103	Aurora B	95	EIF2AK3	96	YES1	14		
PKBb	74	TLK1	116	HIPK1	120	ABL	43		
SGK1	134	LKB1	91	HIPK2	87	BTK	58		
S6K1	114	AMPK	100	HIPK3	87	JAK2	108		
PKA	83	MARK1	101	CLK2	118	SYK	137		
ROCK 2	101	MARK2	111	PAK2	100	ZAP70	103		
PRK2	100	MARK3	84	PAK4	106	TIE2	101		
PKCa	105	MARK4	97	PAK5	104	BRK	79		
PKC γ	99	BRSK1	92	PAK6	96	EPH-A2	6		
PKC ζ	101	BRSK2	83	MST2	111	EPH-A4	5		
PKD1	80	MELK	101	MST4	103	EPH-B1	10		
STK33	84	NUAK1	109	GCK	93	EPH-B2	8		
MSK1	85	TSSK1	98	MINK1	99	EPH-B3	13		

NCI-data on the anti-proliferative activity of compound 3

National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : 752203 / 1	Experiment ID : 1004NS26	Test Type : 08	Units : Molar
Report Date : May 30, 2010	Test Date : April 05, 2010	QNS :	MC :
COMI : compound 66 (92094)	Stain Reagent : SRB Dual-Pass Related	SSPL : 0XTH	

Panel/Cell Line	Time	Log10 Concentration											GI50	TGI	LC50	
		Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0				-4.0
Leukemia																
CCRF-CEM	0.475	2.192	2.244	2.267	2.259	2.153	1.392	103	104	104	98	53	> 1.00E-4	> 1.00E-4	> 1.00E-4	
HL-60(TB)	0.317	2.180	2.019	2.117	2.529	2.602	1.302	91	97	119	123	53	> 1.00E-4	> 1.00E-4	> 1.00E-4	
K-562	0.137	1.947	1.869	1.513	0.555	0.532	0.590	96	76	23	22	25	3.10E-7	> 1.00E-4	> 1.00E-4	
MOLT-4	0.389	2.145	2.142	2.083	1.902	1.883	1.224	100	96	86	85	48	8.59E-5	> 1.00E-4	> 1.00E-4	
RPMI-8226	0.815	2.124	2.248	2.324	2.357	2.277	1.633	109	115	118	112	63	> 1.00E-4	> 1.00E-4	> 1.00E-4	
SR	0.274	1.928	1.755	1.803	1.650	1.521	1.009	90	92	83	75	44	6.60E-5	> 1.00E-4	> 1.00E-4	
Non-Small Cell Lung Cancer																
A549/ATCC	0.326	1.730	1.664	1.627	1.624	1.137	0.684	95	93	92	58	25	1.74E-5	> 1.00E-4	> 1.00E-4	
EKVX	0.620	1.705	1.651	1.591	1.509	1.163	0.924	95	90	82	50	28	1.01E-5	> 1.00E-4	> 1.00E-4	
HOP-62	0.355	1.045	1.055	1.042	1.064	0.655	0.559	101	100	103	43	30	7.74E-6	> 1.00E-4	> 1.00E-4	
NCI-H226	0.675	1.216	1.232	1.211	1.190	1.156	0.921	103	99	95	89	45	7.87E-5	> 1.00E-4	> 1.00E-4	
NCI-H23	0.321	0.966	0.944	0.929	0.874	0.793	0.603	97	94	86	73	44	6.09E-5	> 1.00E-4	> 1.00E-4	
NCI-H322M	0.659	1.714	1.702	1.725	1.647	0.973	1.035	99	101	94	30	36	4.82E-6	> 1.00E-4	> 1.00E-4	
NCI-H460	0.212	1.778	1.792	1.662	1.680	1.470	1.079	101	93	94	80	55	> 1.00E-4	> 1.00E-4	> 1.00E-4	
NCI-H522	0.610	1.689	1.660	1.586	1.222	0.934	0.920	97	90	57	30	29	1.79E-6	> 1.00E-4	> 1.00E-4	
Colon Cancer																
COLO 205	0.378	1.520	1.621	1.664	1.624	1.301	0.235	109	113	109	81	-38	1.82E-5	4.80E-5	> 1.00E-4	
HCC-2998	0.635	1.679	1.624	1.605	1.730	1.639	1.476	95	93	105	96	81	> 1.00E-4	> 1.00E-4	> 1.00E-4	
HCT-116	0.254	1.523	1.507	1.518	1.449	1.047	0.559	99	100	94	62	24	2.11E-5	> 1.00E-4	> 1.00E-4	
HCT-15	0.304	2.087	1.959	1.926	1.849	1.563	1.065	93	91	87	71	43	5.47E-5	> 1.00E-4	> 1.00E-4	
HT29	0.186	1.000	1.010	0.908	0.715	0.174	0.117	101	89	65	-6	-37	1.62E-6	8.12E-6	> 1.00E-4	
KM12	0.412	2.034	2.037	1.936	1.893	1.773	1.431	100	94	91	84	63	> 1.00E-4	> 1.00E-4	> 1.00E-4	
SW-620	0.202	1.044	1.026	1.015	1.017	1.103	0.893	98	96	97	107	82	> 1.00E-4	> 1.00E-4	> 1.00E-4	
CNS Cancer																
SF-268	0.523	1.687	1.695	1.612	1.429	0.969	0.902	101	94	78	38	33	5.07E-6	> 1.00E-4	> 1.00E-4	
SF-295	0.649	1.455	1.287	1.305	1.243	0.980	0.936	79	81	74	41	36	5.34E-6	> 1.00E-4	> 1.00E-4	
SF-539	0.735	2.227	2.188	2.116	1.980	1.454	1.005	97	93	83	48	18	8.86E-6	> 1.00E-4	> 1.00E-4	
SNB-19	0.589	1.914	1.908	2.066	2.056	1.527	1.310	100	111	111	71	54	> 1.00E-4	> 1.00E-4	> 1.00E-4	
SNB-75	0.629	1.081	1.000	0.882	0.638	0.400	0.406	82	56	2	-36	-35	1.29E-7	1.12E-6	> 1.00E-4	
U251	0.286	1.497	1.480	1.464	1.414	0.966	0.752	99	97	93	56	38	2.22E-5	> 1.00E-4	> 1.00E-4	
Melanoma																
LOX IMVI	0.184	1.070	1.017	0.968	0.827	0.269	0.116	94	88	72	10	-37	2.28E-6	1.60E-5	> 1.00E-4	
MALME-3M	0.710	1.611	1.523	1.531	1.426	1.364	1.340	90	91	79	73	70	> 1.00E-4	> 1.00E-4	> 1.00E-4	
M14	0.221	0.806	0.813	0.779	0.718	0.690	0.506	101	95	85	80	49	9.08E-5	> 1.00E-4	> 1.00E-4	
MDA-MB-435	0.475	1.684	1.602	1.593	1.539	1.435	1.102	93	93	88	79	52	> 1.00E-4	> 1.00E-4	> 1.00E-4	
SK-MEL-2	0.702	1.858	1.923	1.796	1.961	1.743	1.511	106	95	109	90	70	> 1.00E-4	> 1.00E-4	> 1.00E-4	
SK-MEL-28	0.510	1.336	1.365	1.327	1.289	1.290	1.065	103	99	94	94	67	> 1.00E-4	> 1.00E-4	> 1.00E-4	
SK-MEL-5	0.663	2.508	2.441	2.407	2.371	1.999	1.430	96	95	93	72	42	5.32E-5	> 1.00E-4	> 1.00E-4	
UACC-257	0.658	1.680	1.631	1.633	1.590	1.462	1.329	95	95	91	79	66	> 1.00E-4	> 1.00E-4	> 1.00E-4	
UACC-62	0.723	2.437	2.453	2.501	2.329	1.961	1.581	101	104	94	72	50	> 1.00E-4	> 1.00E-4	> 1.00E-4	
Ovarian Cancer																
IGROV1	0.476	1.846	2.041	2.117	1.954	0.504	0.418	114	120	108	2	-12	3.52E-6	1.39E-5	> 1.00E-4	
OVCAR-3	0.464	1.425	1.458	1.441	1.224	0.781	0.744	103	102	79	33	29	4.28E-6	> 1.00E-4	> 1.00E-4	
OVCAR-4	0.513	1.304	1.328	1.253	1.292	1.233	0.985	103	93	98	91	60	> 1.00E-4	> 1.00E-4	> 1.00E-4	
OVCAR-5	0.588	1.420	1.356	1.347	1.336	1.165	0.807	92	91	90	69	26	2.81E-5	> 1.00E-4	> 1.00E-4	
OVCAR-8	0.301	1.230	1.336	1.292	1.210	0.773	0.574	111	107	98	51	29	1.09E-5	> 1.00E-4	> 1.00E-4	
NCI/ADR-RES	0.389	1.169	1.165	1.139	1.130	1.069	0.822	99	96	95	87	55	> 1.00E-4	> 1.00E-4	> 1.00E-4	
SK-OV-3	0.453	0.956	0.967	0.938	0.823	0.557	0.472	102	96	73	21	4	2.78E-6	> 1.00E-4	> 1.00E-4	
Renal Cancer																
786-0	0.635	1.573	1.691	1.689	1.536	0.993	0.874	113	112	96	38	25	6.24E-6	> 1.00E-4	> 1.00E-4	
A498	1.024	1.564	1.489	1.415	1.413	1.456	1.050	86	72	72	80	5	2.50E-5	> 1.00E-4	> 1.00E-4	
ACHN	0.392	1.698	1.663	1.619	1.269	0.521	0.383	97	94	67	10	-2	1.99E-6	6.35E-5	> 1.00E-4	
CAKI-1	0.828	1.224	1.256	1.263	1.272	0.662	0.234	108	110	112	-20	-72	2.95E-6	7.05E-6	3.80E-5	
RXF 393	0.833	1.395	1.353	1.343	1.100	0.585	0.618	92	91	47	-30	-26	8.72E-7	4.11E-6	> 1.00E-4	
SN12C	0.625	2.387	2.364	2.323	1.966	1.296	1.098	99	96	76	38	27	4.85E-6	> 1.00E-4	> 1.00E-4	
TK-10	0.715	1.394	1.394	1.375	1.348	1.128	0.518	100	97	93	61	-28	1.33E-5	4.87E-5	> 1.00E-4	
UO-31	0.464	1.639	1.605	1.599	1.469	1.039	0.708	97	97	86	49	21	9.33E-6	> 1.00E-4	> 1.00E-4	
Prostate Cancer																
PC-3	0.557	1.787	1.775	1.749	1.749	1.648	1.174	99	97	97	89	50	> 1.00E-4	> 1.00E-4	> 1.00E-4	
DU-145	0.304	1.151	1.169	1.133	1.089	0.663	0.481	102	98	93	42	21	7.04E-6	> 1.00E-4	> 1.00E-4	
Breast Cancer																
MCF7	0.376	1.841	1.748	1.683	1.628	1.421	1.314	94	89	85	71	64	> 1.00E-4	> 1.00E-4	> 1.00E-4	
MDA-MB-231/ATCC	0.571	1.359	1.431	1.375	1.149	0.770	0.594	109	102	73	25	3	3.06E-6	> 1.00E-4	> 1.00E-4	
HS 578T	0.680	1.187	1.173	1.108	0.877	0.597	0.578	97	84	39	-12	-15	5.67E-7	5.75E-6	> 1.00E-4	
BT-549	1.008	1.393	1.442	1.575	1.574	1.282	1.022	113	147	147	71	4	2.05E-5	> 1.00E-4	> 1.00E-4	
T-47D	0.407	0.905	0.881	0.907	0.905	0.708	0.625	95	101	100	60	44	4.24E-5	> 1.00E-4	> 1.00E-4	
MDA-MB-468	0.563	1.386	1.314	1.334	1.285	1.072	0.573	91	94	88	62	1	1.56E-5	> 1.00E-4	> 1.00E-4	

Experimental section

Chemistry

Experimental details can be found in the main text of the article. For compounds **24**, **28**, **30**, **31**, **37**, **39**, **40**, **46** and **50** further spectroscopic data can also be found under the Experimental Section of the article.

1-(4-Fluoro-2-methylphenyl)ethanol (**6**)

To a solution of 4-fluoro-2-methylbenzaldehyde (**5**, 0.8 mL, 6.62 mmol) in THF (20 mL) at -78 °C was added MeLi (1.6 M, 5.2 mL, 8.28 mmol) dropwise. The reaction was allowed to warm to room temperature and stirred for an additional hour. The reaction was quenched by addition of EtOAc, followed by water. The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was immediately purified by column chromatography (gradient hexane:EtOAc 20:1 to 10:1) to afford the desired compound as a colorless oil (559 mg, 55% yield). ¹H NMR (400 MHz, CDCl₃): δ = 7.46 (dd, *J* = 8.6 Hz, *J* = 5.9 Hz, 1H), 6.93-6.88 (m, 1H), 6.83 (dd, *J* = 9.7 Hz, *J* = 2.7 Hz, 1H), 5.08 (q, *J* = 6.4 Hz, 1H), 2.33 (s, 3H), 1.44 (d, *J* = 6.4 Hz, 3H), OH not observed; ¹³C NMR (100 MHz, CDCl₃): δ = 161.7 (d, *J* = 244.7 Hz), 139.5 (d, *J* = 3 Hz), 136.6 (d, *J* = 7.7 Hz), 126.3 (d, *J* = 8.4 Hz), 116.8 (d, *J* = 20.9 Hz), 112.9 (d, *J* = 20.8 Hz), 66.4, 24.1, 18.9 (d, *J* = 1.4 Hz); IR (film): $\tilde{\nu}$ = 2975, 2929, 1681, 1580, 1354, 1234, 1115, 972, 865, 813 cm⁻¹; MS (GC/MS): *m/z*: calcd for C₉H₁₁FO: 154.1, found: 154.0.

1-(4-Fluoro-2-methylphenyl)ethanone (**7**)

1-(4-Fluoro-2-methylphenyl)ethanol (**6**, 559 mg, 3.62 mmol) was dissolved in CH₂Cl₂ (6 mL), and PCC (1.58 g, 7.33 mmol) was added to the mixture. After 1 h at 25 °C, the solution was filtered off over celite, concentrated under reduced pressure, and purified by flash chromatography on silica gel (gradient hexane:EtOAc 99:1 to 95:5) to afford **7** as a colorless oil (403 mg, 73% yield). ¹H NMR (500 MHz, CDCl₃): δ = 7.74 (dd, *J* = 9.4 Hz, *J* = 5.8 Hz, 1H), 6.96-6.92 (m, 2H), 2.56 (s, 3H), 2.55 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ = 199.8, 164.1 (d, *J* = 253.2 Hz), 142.5 (d, *J* = 8.9 Hz), 133.7 (d, *J* = 2.9 Hz), 132.1 (d, *J* = 9.5 Hz), 118.9 (d, *J* = 21.2 Hz), 112.5

(d, $J = 21.4$ Hz), 29.4, 21.9 (d, $J = 1.6$ Hz); IR (film): $\tilde{\nu} = 2975, 2929, 1681, 1580, 1354, 1234, 1115, 972, 865, 813$ cm^{-1} ; MS (ESI): m/z : calcd for $\text{C}_9\text{H}_9\text{FONa}^+$: 175.1, found: 174.9.

1-(2,6-Dimethylphenyl)ethanone (10)

To a solution of 2-bromo-1,3-dimethylbenzene (**8**, 2 mL, 15.01 mmol) in anhydrous THF (20 mL) at -78 °C was added *n*BuLi (2.5 M in hexane, 9.6 mL, 24.02 mmol). The reaction was stirred 30 min at -78 °C. After addition of acetaldehyde (21.8 mL, 390.3 mmol), stirring was continued at -78 °C for 1 h. The reaction was quenched with water, and the organic layer was washed with brine, dried over MgSO_4 , filtered, and concentrated under reduced pressure to afford the crude alcohol (**9**). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.07\text{--}7.03$ (m, 1H), 7.00–6.98 (m, 2H), 5.40 (q, $J = 6.7$ Hz, 1H), 2.45 (s, 6H), 1.54 (d, $J = 6.7$ Hz, 3H), OH not observed; ^{13}C NMR (125 MHz, CDCl_3): $\delta = 140.5, 135.7, 129.4, 126.9, 67.7, 21.4, 20.6$; IR (film): $\tilde{\nu} = 3302, 3019, 2925, 2856, 1583, 1468, 1366, 1298, 1191, 1071, 892$ cm^{-1} ; MS (ESI): m/z : calcd for $\text{C}_{10}\text{H}_{14}\text{ONa}^+$: 173.1, found: 173.0.

The crude intermediate (**9**) was dissolved in CH_2Cl_2 (20 mL), and PCC (3.56 g, 16.51 mmol) was added to the mixture. After 1 h at 25 °C, the solution was filtrated over celite, concentrated under reduced pressure, and purified by flash chromatography on silica gel (hexane/EtOAc 100:1) to afford **10** as a light yellow oil (1.24 g, 56% yield over two steps). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.15$ (t, $J = 7.6$ Hz, 1H), 7.02 (d, $J = 7.6$ Hz, 2H), 2.47 (s, 3H), 2.25 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 208.4, 142.6, 132.2, 128.5, 127.8, 32.1, 19.1$; IR (film): $\tilde{\nu} = 3066, 2954, 2923, 2854, 1697, 1462, 1421, 1350, 1254, 1055, 769$ cm^{-1} ; MS (ESI): m/z : calcd for $\text{C}_{10}\text{H}_{12}\text{ONa}^+$: 171.1, found: 171.0.

1-(3-Amino-2,6-dimethylphenyl)ethanone (12)

To a solution of 1-(2,6-dimethylphenyl)ethanone (**10**, 1.24 g, 8.10 mmol) in H_2SO_4 (10 mL) at 0 °C was added dropwise a solution of KNO_3 (819 mg, 8.10 mmol) in H_2SO_4 (10 mL) over 1 h. The reaction was then quenched by pouring into ice, and the aqueous layer was extracted with EtOAc. The organic solution was washed with brine, dried over MgSO_4 , filtered, and concentrated under reduced pressure to afford the crude intermediate (**11**). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.81$ (d, $J = 8.3$ Hz, 1H), 7.18 (d, $J = 8.3$ Hz, 1H), 2.51 (s, 3H), 2.42 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): $\delta = 205.9, 148.1, 144.7, 138.1, 128.9, 127.7, 124.5, 32.2$,

19.4, 16.4; IR (film): $\tilde{\nu}$ = 3089, 2979, 2915, 2846, 1706, 1514, 1338, 1237, 1094, 841, 754 cm^{-1} ;
HRMS (ESI): m/z : calcd for $\text{C}_{10}\text{H}_{11}\text{NO}_3\text{Na}^+$: 216.0631, found: 216.0631.

The intermediate (**11**) was dissolved in a 1 : 1 glacial acetic acid–ethanol solution (10 mL) and iron (2.26 g, 40.5 mmol) was added in portions. The resulting mixture was stirred at 90 °C for 2 h, filtered through celite, concentrated under reduced pressure, and neutralized with NaHCO_3 . The aqueous layer was extracted with EtOAc, and the organic solution was dried over MgSO_4 , filtered, and concentrated under reduced pressure. Purification by column chromatography on silica gel (hexane/EtOAc 5:1) afforded the desired compound as a light yellow oil (626 mg, 47% yield over two steps). ^1H NMR (400 MHz, CDCl_3): δ = 6.85 (d, J = 8.1 Hz, 1H), 6.60 (d, J = 8.1 Hz, 1H), 3.57 (s, 2H), 2.45 (s, 3H), 2.14 (s, 3H), 2.03 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ = 208.9, 143.2, 142.6, 128.6, 121.8, 116.4, 115.3, 32.4, 18.3, 13.8; IR (film): $\tilde{\nu}$ = 3455, 3369, 3235, 2919, 2862, 1691, 1624, 1482, 1350, 1302, 1242, 815 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{10}\text{H}_{13}\text{NOH}^+$: 164.1070, found: 164.1068.

1,1'-(5-Methyl-1H-indazole-1,4-diyl)diethanone (13)

To a mixture of 1-(3-amino-2,6-dimethylphenyl)ethanone (**12**, 285 mg, 1.74 mmol) and NaOAc (172 mg, 2.09 mmol) in CHCl_3 (3 mL) at 0 °C was added acetic anhydride (0.49 mL, 25.1 mmol) dropwise. After stirring for 30 min at 25 °C, the reaction was heated to 40 °C, and isoamyl nitrite (0.469 mL, 3.49 mmol) was added. The reaction was stirred at 60 °C for 7 h and quenched by the addition of a saturated solution of NaHCO_3 . The resulting solution was extracted with CHCl_3 , dried over MgSO_4 , filtered, and concentrated under reduced pressure. Purification by column chromatography on silica gel (hexane/EtOAc 9:1) afforded the desired compound as a white solid (219 mg, 58% yield). ^1H NMR (500 MHz, CDCl_3): δ = 8.42 (d, J = 8.5 Hz, 1H), 8.18 (d, J = 0.8 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 2.79 (s, 3H), 2.69 (s, 3H), 2.57 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ = 202.3, 171.2, 138.6, 137.8, 133.0, 132.4, 132.0, 124.2, 117.5, 32.1, 23.0, 20.3; IR (film): $\tilde{\nu}$ = 3107, 2979, 2927, 1719, 1686, 1412, 1380, 1356, 1160, 942, 818 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{12}\text{H}_{12}\text{N}_2\text{O}_2\text{Na}^+$: 239.0791, found: 239.0790.

2-Bromo-1-(4-fluoro-2-methylphenyl)ethanone (17)

Colorless oil; Yield: 64%; ^1H NMR (400 MHz, CDCl_3): δ = 7.73 (dd, J = 8.5 Hz, J = 5.7 Hz, 1H), 7.00-6.94 (m, 2H), 4.38 (s, 2H), 2.54 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ = 192.6, 164.5 (d, J = 254.8 Hz), 143.9 (d, J = 8.9 Hz), 131.8 (d, J = 9.7 Hz), 130.4 (d, J = 2.9 Hz), 119.3 (d, J = 21.2 Hz),

112.8 (d, $J = 21.7$ Hz), 33.2, 21.8 (d, $J = 1.3$ Hz); IR (film): $\tilde{\nu} = 2974, 2927, 1678, 1605, 1579, 1258, 1235, 1104, 989, 866, 818$ cm⁻¹; MS (ESI): m/z : calcd for C₉H₈BrFONa⁺: 253.0, found: 252.9.

2-Bromo-1-(2,6-dimethylphenyl)ethanone (18)

Colorless oil; Yield: 21%; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.23-7.19$ (m, 1H), 7.06-7.04 (m, 2H), 4.28 (s, 2H), 2.26 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 200.1, 138.8, 133.4, 129.6, 127.9, 36.5, 19.4$; IR (film): $\tilde{\nu} = 3066, 2925, 2854, 1716, 1695, 1462, 1381, 1261, 1185, 983, 771$ cm⁻¹; MS (ESI): m/z : calcd for C₁₀H₁₁BrONa⁺: 249.0, found: 248.9.

1-(1-Acetyl-5-methyl-1H-indazol-4-yl)-2-bromoethanone (19)

White solid; Yield: 37%; ¹H NMR (400 MHz, CDCl₃): $\delta = 8.47$ (d, $J = 8.6$ Hz, 1H), 8.12 (s, 1H), 7.44 (d, $J = 8.6$ Hz, 1H), 4.43 (s, 2H), 2.80 (s, 3H), 2.57 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 195.8, 171.1, 138.0, 137.8, 132.8, 132.5, 129.2, 124.5, 118.2, 34.9, 23.0, 20.0$; IR (film): $\tilde{\nu} = 2928, 2852, 1712, 1415, 1382, 1152, 946, 823, 677$ cm⁻¹; HRMS (ESI): m/z : calcd for C₁₂H₁₁BrN₂O₂Na⁺: 316.9896, found: 316.9896.

2-Bromo-1-(2-chlorophenyl)ethanone (20)

Light brown oil; Yield: 52%; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.58-7.56$ (m, 1H), 7.46-7.44 (m, 2H), 7.39-7.34 (m, 1H), 4.53 (s, 2H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 194.0, 136.2, 132.7, 131.3, 130.6, 130.2, 127.1, 34.5$; IR (film): $\tilde{\nu} = 3067, 2940, 1697, 1589, 1432, 1285, 1192, 1064, 988, 755$ cm⁻¹; MS (ESI): m/z : calcd for C₈H₆BrClONa⁺: 254.9, found: 254.9.

2-Bromo-1-(3-chlorophenyl)ethanone (21)

Light brown oil; Yield: 31%; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.95$ (t, $J = 1.9$ Hz, 1H), 7.87-7.84 (m, 1H), 7.58 (ddd, $J = 7.9$ Hz, $J = 1.9$ Hz, $J = 0.9$ Hz, 1H), 7.44 (t, $J = 7.9$ Hz, 1H), 4.42 (s, 2H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 190.1, 135.4, 135.2, 133.9, 130.2, 128.9, 127.0, 30.5$; IR (film): $\tilde{\nu} = 3067, 3003, 2950, 1698, 1571, 1422, 1269, 1016, 781$ cm⁻¹; MS (ESI): m/z : calcd for C₈H₆BrClONa⁺: 254.9, found: 254.9.

2-Bromo-1-(2-(trifluoromethyl)phenyl)ethanone (22)

Light brown oil; Yield: 55%; ^1H NMR (500 MHz, CDCl_3): δ = 7.75 (dd, J = 7.2 Hz, J = 1.5 Hz, 1H), 7.67-7.61 (m, 2H), 7.52 (dd, J = 7.2 Hz, J = 1.5 Hz, 1H), 4.40 (s, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ = 194.9, 136.3 (q, J = 2 Hz), 132.0, 131.1, 127.8, 127.4 (q, J = 32.4 Hz), 126.9 (q, J = 4.9 Hz), 123.2 (q, J = 273.6 Hz), 34.4 (q, J = 2.2 Hz); IR (film): $\tilde{\nu}$ = 2943, 1725, 1703, 1312, 1275, 1167, 1125, 1063, 1034, 766 cm^{-1} ; MS (ESI): m/z : calcd for $\text{C}_9\text{H}_6\text{BrF}_3\text{ONa}^+$: 289.0, found: 288.9.

8-Bromo-3-methyl-7-(2-oxo-2-(*o*-tolyl)ethyl)-1H-purine-2,6(3H,7H)-dione (24)

^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ = 194.1, 153.9, 150.4, 148.9, 138.3, 133.7, 132.7, 131.9, 129.1, 129.0, 126.1, 108.8, 54.3, 28.5, 20.6; IR (film): $\tilde{\nu}$ = 3154, 3025, 2814, 1676, 1535, 1364, 1208, 768 cm^{-1} .

8-Bromo-7-(2-(4-fluoro-2-methylphenyl)-2-oxoethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (25)

White solid; Yield: 56%; ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ = 11.35 (s, 1H), 8.20-8.17 (m, 1H), 7.30-7.29 (m, 2H), 5.79 (s, 2H), 3.36 (s, 3H), 2.44 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ = 192.7, 164.0 (d, J = 252 Hz), 154.0, 150.5, 149.0, 142.9 (d, J = 9.2 Hz), 132.4 (d, J = 9.9 Hz), 130.3 (d, J = 2.7 Hz), 129.2, 118.8 (d, J = 21.5 Hz), 113.1 (d, J = 21.4 Hz), 108.8, 54.3, 28.6, 20.9; IR (film): $\tilde{\nu}$ = 3152, 3032, 2813, 1671, 1534, 1369, 1237, 1200, 990, 865 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{15}\text{H}_{12}\text{BrFN}_4\text{O}_3\text{Na}^+$: 416.9969, found: 416.9967.

8-Bromo-7-(2-(3-chlorophenyl)-2-oxoethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (26)

White solid; Yield: 75%; ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ = 11.34 (s, 1H), 8.16 (t, J = 1.9 Hz, 1H), 8.07-8.05 (m, 1H), 7.85 (ddd, J = 7.9 Hz, J = 1.9 Hz, J = 0.9 Hz, 1H), 7.66 (t, J = 7.9 Hz, 1H), 5.96 (s, 2H), 3.36 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ = 190.7, 153.9, 150.5, 149.1, 135.4, 134.2, 134.0, 131.1, 129.1, 128.0, 126.9, 108.9, 53.0, 28.6; IR (film): $\tilde{\nu}$ = 3143, 3000, 2818, 1680, 1537, 1438, 1364, 1210, 876 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{14}\text{H}_{10}\text{BrClN}_4\text{O}_3\text{Na}^+$: 418.9517, found: 418.9515.

8-Bromo-7-(2-(2-chlorophenyl)-2-oxoethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (27)

White solid; Yield: 63%; ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ = 11.38 (s, 1H), 7.96-7.94 (m, 1H), 7.68-7.65 (m, 2H), 7.61-7.56 (m, 1H), 5.80 (s, 2H), 3.36 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ = 193.0, 154.0, 150.5, 149.0, 134.4, 133.8, 131.0, 130.6, 130.1, 129.1, 127.7, 108.7, 54.9, 28.6; IR (film): $\tilde{\nu}$ = 3161, 3052, 2948, 2835, 1680, 1541, 1430, 1353, 1199, 838, 746 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{14}\text{H}_{10}\text{BrClN}_4\text{O}_3\text{Na}^+$: 418.9517, found: 418.9517.

8-Bromo-3-methyl-7-(2-oxo-2-(2-(trifluoromethyl)phenyl)ethyl)-1H-purine-2,6(3H,7H)-dione (28)

^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ = 194.8, 154.1, 150.5, 149.1, 135.2 (q, J = 2 Hz), 132.9, 132.3, 129.0, 128.5, 127.2 (q, J = 4.9 Hz), 126.2 (q, J = 32.2 Hz), 123.3 (q, J = 273.8 Hz), 108.7, 55.1, 28.6; IR (film): $\tilde{\nu}$ = 3163, 3046, 2940, 2807, 1708, 1674, 1359, 1318, 1213, 1165, 1111, 773 cm^{-1} .

8-Bromo-7-(2-(2,6-dimethylphenyl)-2-oxoethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (29)

3-Methyl-8-bromoxanthine (**4**, 240 mg, 0.98 mmol) was dissolved in DMF (2.5 mL), and *N,N*-diisopropylethylamine (0.256 mL, 1.47 mmol) was added. After stirring for 5 min at 25 °C, 2-bromo-1-(2,6-dimethylphenyl)ethanone (**18**, 222 mg, 0.98 mmol) was added. The reaction was stirred at 110 °C for 2 h. The mixture was then concentrated under reduced pressure, methanol was added and the formed precipitate was filtered off and washed with water to afford the product as a white solid (226 mg, 59% yield). ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ = 11.38 (s, 1H), 7.31 (t, J = 7.6 Hz, 1H), 7.15 (d, J = 7.6 Hz, 2H), 5.63 (s, 2H), 3.37 (s, 3H), 2.34 (s, 6H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$, CDCl_3): δ = 201.0, 154.0, 150.4, 149.1, 137.5, 133.5, 129.7, 129.2, 127.8, 108.8, 56.5, 28.6, 18.8; IR (film): $\tilde{\nu}$ = 3150, 3019, 2956, 2829, 1668, 1363, 1199, 969, 780 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{16}\text{H}_{15}\text{BrN}_4\text{O}_3\text{H}^+$: 391.0400, found: 391.0405.

7-(2-(1-Acetyl-5-methyl-1H-indazol-4-yl)-2-oxoethyl)-8-bromo-3-methyl-1H-purine-2,6(3H,7H)-dione (30)

^{13}C NMR (125 MHz, DMSO- d_6): δ = 196.5, 170.8, 154.2, 150.5, 149.2, 137.8, 136.9, 133.0, 132.2, 129.3, 128.7, 123.5, 117.2, 108.8, 56.5, 28.6, 22.7, 19.0; IR (film): $\tilde{\nu}$ = 3165, 3049, 2948, 2820, 1722, 1702, 1675, 1371, 1207, 1154, 1105, 942, 816 cm^{-1} .

8-(Butylamino)-7-(2-(butylimino)-2-(*o*-tolyl)ethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (31)

^{13}C NMR (125 MHz, DMSO- d_6): δ = 163.7, 155.2, 153.1, 150.9, 150.0, 135.7, 134.4, 129.8, 128.6, 126.8, 125.7, 102.0, 51.0, 49.3, 41.9, 32.1, 31.4, 28.3, 19.5, 19.3, 18.6, 13.7, 13.6; IR (film): $\tilde{\nu}$ = 3329, 3141, 2954, 2929, 2869, 2806, 1671, 1611, 1573, 1438, 1300, 1225, 1113, 753 cm^{-1} .

3-Methyl-8-(pentylamino)-7-(2-(pentylimino)-2-(*o*-tolyl)ethyl)-1H-purine-2,6(3H,7H)-dione (32)

White solid; ^1H NMR (500 MHz, DMSO- d_6): δ = 10.53 (s, 1H), 7.31-7.25 (m, 4H), 6.90 (t, J = 5.6 Hz, 1H), 4.97 (d, J = 18.2 Hz, 1H), 4.86 (d, J = 18.2 Hz, 1H), 3.33 (s, 2H), 3.29 (s, 3H), 3.01-2.97 (m, 1H), 2.82-2.77 (m, 1H), 2.17 (s, 3H), 1.58-1.55 (m, 2H), 1.33-1.26 (m, 6H), 1.10-1.00 (m, 4H), 0.88 (t, J = 6.8 Hz, 3H), 0.75 (t, J = 6.9 Hz, 3H); ^{13}C NMR (125 MHz, DMSO- d_6): δ = 163.6, 155.3, 153.1, 150.9, 150.0, 135.7, 134.4, 129.8, 128.6, 126.7, 125.7, 102.0, 51.1, 49.4, 42.2, 29.5, 28.9, 28.6, 28.4, 28.3, 21.9, 21.8, 18.6, 13.9, 13.8; IR (film): $\tilde{\nu}$ = 3340, 3144, 3015, 2955, 2924, 2855, 2802, 1657, 1614, 1579, 1437, 1219, 1098, 752 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{25}\text{H}_{36}\text{N}_6\text{O}_2\text{H}^+$: 453.2973, found: 453.2970.

8-(Hexylamino)-7-(2-(hexylimino)-2-(*o*-tolyl)ethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (33)

White solid; ^1H NMR (500 MHz, DMSO- d_6): δ = 10.52 (s, 1H), 7.31-7.25 (m, 4H), 6.90 (t, J = 5.6 Hz, 1H), 4.97 (d, J = 17.7 Hz, 1H), 4.86 (d, J = 17.7 Hz, 1H), 3.33 (s, 2H), 3.29 (s, 3H), 3.00-2.96 (m, 1H), 2.82-2.77 (m, 1H), 2.17 (s, 3H), 1.58-1.52 (m, 2H), 1.35-1.25 (m, 8H), 1.17-1.02 (m, 6H), 0.87 (t, J = 6.8 Hz, 3H), 0.78 (t, J = 7.3 Hz, 3H); ^{13}C NMR (125 MHz, DMSO- d_6): δ = 163.6, 155.3, 153.1, 150.9, 150.0, 135.8, 134.4, 129.8, 128.6, 126.8, 125.6, 102.0, 51.1, 49.3, 42.2, 31.0, 30.9, 29.8, 29.2, 28.2, 26.0, 25.9, 22.1, 21.9, 18.6, 13.9, 13.8; IR (film): $\tilde{\nu}$ = 3338, 3149, 3015, 2953, 2924, 2854, 1659, 1614, 1550, 1486, 1439, 1301, 1218, 1099, 752 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{27}\text{H}_{40}\text{N}_6\text{O}_2\text{H}^+$: 481.3286, found: 481.3286.

8-(Butylamino)-7-(2-(butylimino)-2-(4-fluoro-2-methylphenyl)ethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (34)

Light brown solid; ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ = 10.50 (s, 1H), 7.37-7.32 (m, 1H), 7.15-7.13 (m, 2H), 6.87 (t, J = 5.7 Hz, 1H), 4.98 (d, J = 18.4 Hz, 1H), 4.83 (d, J = 18.4 Hz, 1H), 3.31 (s, 5H), 3.04-2.98 (m, 1H), 2.83-2.77 (m, 1H), 2.18 (s, 3H), 1.58-1.51 (m, 2H), 1.38-1.32 (m, 2H), 1.29-1.24 (m, 2H), 1.14-1.03 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H), 0.70 (t, J = 7.3 Hz, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ = 162.9, 161.9 (d, J = 244.7 Hz), 155.2, 153.1, 150.9, 150.0, 137.8 (d, J = 8.2 Hz), 132.0 (d, J = 3.1 Hz), 129.0 (d, J = 8.8 Hz), 116.4 (d, J = 21.2 Hz), 112.6 (d, J = 21.0 Hz), 101.9, 51.0, 49.4, 41.9, 32.0, 31.4, 28.3, 19.5, 19.3, 18.6, 13.7, 13.6; IR (film): $\tilde{\nu}$ = 3330, 3141, 2956, 2930, 2870, 1672, 1656, 1612, 1573, 1439, 1300, 1226, 1116, 856, 754 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{23}\text{H}_{31}\text{FN}_6\text{O}_2\text{H}^+$: 443.2565, found: 443.2564.

8-(Butylamino)-7-(2-(butylimino)-2-(3-chlorophenyl)ethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (35)

White solid; ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ = 10.53 (s, 1H), 7.52-7.50 (m, 2H), 7.43 (s, 1H), 7.24-7.21 (m, 1H), 6.86 (t, J = 5.4 Hz, 1H), 4.97 (s, 2H), 3.31 (s, 2H), 3.28 (s, 3H), 3.08 (t, J = 6.6 Hz, 2H), 1.58-1.51 (m, 2H), 1.40-1.27 (m, 4H), 1.06-1.15 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H), 0.71 (t, J = 7.3 Hz, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ = 162.0, 154.9, 153.2, 150.9, 150.0, 137.6, 133.3, 130.5, 128.7, 126.7, 125.6, 101.8, 51.2, 49.3, 41.9, 32.3, 31.4, 28.3, 19.5, 19.4, 13.7, 13.6; IR (film): $\tilde{\nu}$ = 3361, 3154, 2956, 2862, 1668, 1615, 1570, 1544, 1443, 1223, 749 cm^{-1} .

8-(Butylamino)-7-(2-(butylimino)-2-(2-chlorophenyl)ethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (36)

White solid; ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ = 10.52 (s, 1H), 7.53-7.39 (m, 4H), 6.81 (t, J = 5.4 Hz, 1H), 5.08 (d, J = 17.7 Hz, 1H), 4.92 (d, J = 17.7 Hz, 1H), 3.34 (s, 2H), 3.28 (s, 3H), 3.09-3.07 (m, 1H), 2.86-2.84 (m, 1H), 1.53 (quint, J = 7.3 Hz, 2H), 1.39-1.29 (m, 4H), 1.15-1.06 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H), 0.71 (t, J = 7.3 Hz, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ = 160.8, 155.2, 153.1, 150.9, 150.0, 134.5, 130.6, 130.1, 129.1, 129.0, 127.3, 102.0, 51.5, 49.1, 41.9, 31.9, 31.3, 28.3, 19.5, 19.3, 13.7, 13.6; IR (film): $\tilde{\nu}$ = 3316, 3139, 2955, 2858, 2812, 1672, 1614, 1444, 1303, 1225, 1133, 875, 750 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{22}\text{H}_{29}\text{ClN}_6\text{O}_2\text{H}^+$: 445.2113, found: 445.2115.

8-Butyl-1-methyl-7-(*o*-tolyl)-1H-imidazo[2,1-*f*]purine-2,4(3H,8H)-dione (40)

^{13}C NMR (125 MHz, DMSO- d_6): δ = 153.3, 152.7, 151.0, 147.3, 138.2, 131.5, 130.4, 130.3, 129.8, 127.0, 125.9, 105.7, 98.9, 42.8, 30.1, 28.8, 19.6, 18.7, 13.0; IR (film): $\tilde{\nu}$ = 3165, 3062, 2955, 2872, 1698, 1670, 1505, 1456, 1146, 774, 721 cm^{-1} .

1-Methyl-8-pentyl-7-(*o*-tolyl)-1H-imidazo[2,1-*f*]purine-2,4(3H,8H)-dione (41)

White solid; Yield: 37% over two steps; mp 206-208 °C; ^1H NMR (500 MHz, DMSO- d_6): δ = 10.94 (s, 1H), 7.62 (s, 1H), 7.47-7.33 (m, 4H), 3.82 (t, J = 7.1 Hz, 2H), 3.40 (s, 3H), 2.24 (s, 3H), 1.56 (quint, J = 7.1 Hz, 2H), 1.12-0.99 (m, 4H), 0.71 (t, J = 7.1 Hz, 3H); ^{13}C NMR (125 MHz, DMSO- d_6): δ = 153.3, 152.7, 151.0, 147.3, 138.1, 131.5, 130.4, 130.3, 129.8, 127.1, 125.9, 105.7, 98.9, 43.0, 28.8, 27.6, 27.6, 21.2, 19.6, 13.5; IR (film): $\tilde{\nu}$ = 3156, 3013, 2930, 2868, 2820, 1674, 1514, 1455, 1297, 1153, 848, 725 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{20}\text{H}_{23}\text{N}_5\text{O}_2\text{Na}^+$: 388.1744, found: 388.1742.

8-Hexyl-1-methyl-7-(*o*-tolyl)-1H-imidazo[2,1-*f*]purine-2,4(3H,8H)-dione (42)

White solid; Yield: 38% over two steps; mp 202-204 °C; ^1H NMR (500 MHz, DMSO- d_6): δ = 10.94 (s, 1H), 7.62 (s, 1H), 7.46-7.33 (m, 4H), 3.82 (t, J = 7.1 Hz, 2H), 3.40 (s, 3H), 2.24 (s, 3H), 1.56 (quint, J = 7.1 Hz, 2H), 1.12-1.02 (m, 6H), 0.74 (t, J = 7.1 Hz, 3H); ^{13}C NMR (125 MHz, DMSO- d_6): δ = 153.3, 152.7, 151.0, 147.3, 138.1, 131.5, 130.4, 130.3, 129.8, 127.1, 125.9, 105.7, 98.9, 43.0, 30.2, 28.8, 27.8, 25.1, 21.7, 19.6, 13.7; IR (film): $\tilde{\nu}$ = 3155, 3016, 2928, 2856, 2823, 1671, 1514, 1455, 1154, 851, 725 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{21}\text{H}_{25}\text{N}_5\text{O}_2\text{Na}^+$: 402.1901, found: 402.1905.

8-Butyl-7-(4-fluoro-2-methylphenyl)-1-methyl-1H-imidazo[2,1-*f*]purine-2,4(3H,8H)-dione (43)

White solid; Yield: 43% over two steps; mp 240-242 °C; ^1H NMR (500 MHz, DMSO- d_6): δ = 10.94 (s, 1H), 7.63 (s, 1H), 7.49-7.46 (m, 1H), 7.30 (d, J = 9.3 Hz, 1H), 7.22-7.19 (m, 1H), 3.81 (t, J = 7.1 Hz, 2H), 3.40 (s, 3H), 2.24 (s, 3H), 1.55 (quint, J = 7.1 Hz, 2H), 1.08 (sext, J = 7.1 Hz, 2H), 0.70 (t, J = 7.1 Hz, 3H); ^{13}C NMR (125 MHz, DMSO- d_6): δ = 162.6 (d, J = 246.7 Hz), 153.3, 152.7, 151.0, 147.3, 141.5 (d, J = 8.5 Hz), 133.7 (d, J = 8.5 Hz), 129.2, 123.5 (d, J = 2.9 Hz), 116.9 (d, J = 21.5 Hz), 112.9 (d, J = 21.4 Hz), 106.0, 98.9, 42.8, 30.1, 28.8, 19.6, 18.8, 13.1; IR (film): $\tilde{\nu}$ = 3161,

3034, 2952, 2871, 2819, 1698, 1672, 1509, 1445, 1311, 1192, 1141, 861, 746 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{19}\text{H}_{20}\text{FN}_5\text{O}_2\text{Na}^+$: 392.1493, found: 392.1495.

8-Butyl-7-(3-chlorophenyl)-1-methyl-1H-imidazo[2,1-*f*]purine-2,4(3H,8H)-dione (44)

White solid; Yield: 41% over two steps; mp 259-261 °C; ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ = 10.98 (s, 1H), 7.84 (s, 1H), 7.72-7.71 (m, 1H), 7.58-7.56 (m, 3H), 4.12 (t, J = 7.3 Hz, 2H), 3.40 (s, 3H), 1.61 (quint, J = 7.3 Hz, 2H), 1.12 (sext, J = 7.3 Hz, 2H), 0.74 (t, J = 7.3 Hz, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ = 153.2, 152.9, 151.0, 148.0, 133.6, 130.8, 130.6, 130.1, 128.9, 128.5, 127.5, 106.0, 98.9, 43.5, 30.2, 28.9, 18.8, 13.1; IR (film): $\tilde{\nu}$ = 3153, 3027, 2969, 2929, 2859, 2826, 1686, 1507, 1442, 1226, 1138, 786 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{18}\text{H}_{18}\text{ClN}_5\text{O}_2\text{H}^+$: 372.1222, found: 372.1223.

8-Butyl-7-(2-chlorophenyl)-1-methyl-1H-imidazo[2,1-*f*]purine-2,4(3H,8H)-dione (45)

White solid; Yield: 34% over two steps; mp 236-238 °C; ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ = 10.97 (s, 1H), 7.72-7.69 (m, 2H), 7.64-7.59 (m, 2H), 7.55-7.52 (m, 1H), 3.87 (t, J = 7.3 Hz, 2H), 3.40 (s, 3H), 1.57 (quint, J = 7.3 Hz, 2H), 1.08 (sext, J = 7.3 Hz, 2H), 0.69 (t, J = 7.3 Hz, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ = 153.3, 152.9, 151.0, 147.3, 134.2, 133.6, 131.9, 129.8, 128.4, 127.6, 126.6, 106.5, 98.9, 43.3, 30.1, 28.9, 18.7, 13.0; IR (film): $\tilde{\nu}$ = 3176, 3064, 2963, 2875, 2804, 1698, 1669, 1504, 1455, 1148, 768 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{18}\text{H}_{18}\text{ClN}_5\text{O}_2\text{H}^+$: 372.1222, found: 372.1224.

7-(3-Chlorophenyl)-8-(2-methoxyphenyl)-1-methyl-1H-imidazo[2,1-*f*]purine-2,4(3H,8H)-dione (47)

White solid; Yield: 45%; mp 313-315 °C; ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ = 10.98 (s, 1H), 8.16 (s, 1H), 7.58 (dd, J = 7.7 Hz, J = 1.6 Hz, 1H), 7.54 (td, J = 7.7 Hz, J = 1.6 Hz, 1H), 7.38-7.30 (m, 3H), 7.22-7.19 (m, 2H), 7.14 (td, J = 7.6 Hz, J = 1.1 Hz, 1H), 3.58 (s, 3H), 3.28 (s, 3H); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ = 154.7, 153.3, 152.9, 151.0, 148.1, 133.0, 131.5, 131.3, 130.3, 130.2, 129.8, 128.1, 126.9, 125.7, 122.3, 121.1, 113.0, 106.3, 99.2, 55.7, 28.9; IR (film): $\tilde{\nu}$ = 3169, 3022, 2826, 1708, 1670, 1505, 1434, 1161, 849, 740 cm^{-1} ; HRMS (ESI): m/z : calcd for $\text{C}_{21}\text{H}_{16}\text{ClN}_5\text{O}_3\text{H}^+$: 422.1014, found: 422.1012.

7-(2-Chlorophenyl)-8-(2-methoxyphenyl)-1-methyl-1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione (48)

White solid; Yield: 32%; mp 305-307 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.00 (s, 1H), 7.89 (s, 1H), 7.52-7.46 (m, 2H), 7.43-7.36 (m, 3H), 7.31-7.27 (m, 1H), 7.08-7.02 (m, 2H), 3.57 (s, 3H), 3.28 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆): δ = 154.3, 153.4, 152.9, 151.0, 147.3, 133.7, 133.0, 131.1, 131.1, 129.6, 129.5, 129.3, 126.8, 126.7, 121.7, 120.6, 112.5, 107.2, 99.1, 55.4, 28.8; IR (film): $\tilde{\nu}$ = 3150, 3044, 2821, 1665, 1509, 1490, 1422, 1280, 1159, 764 cm⁻¹; HRMS (ESI): *m/z*: calcd for C₂₁H₁₆ClN₅O₃H⁺: 422.1014, found: 422.1016.

Synthesis of compound 46

8-(Butylamino)-3-methyl-7-(2-oxo-2-(2-(trifluoromethyl)phenyl)ethyl)-1H-purine-2,6(3H,7H)-dione (37)

¹³C NMR (125 MHz, DMSO-*d*₆): δ = 195.2, 154.8, 153.2, 150.8, 150.2, 135.3, 132.6, 132.2, 129.3, 127.2 (q, *J* = 5.4 Hz), 126.4 (q, *J* = 32.2 Hz), 123.2 (q, *J* = 273.8 Hz), 101.6, 51.5, 41.9, 31.2, 28.3, 19.2, 13.6; IR (film): $\tilde{\nu}$ = 3379, 3153, 3035, 2939, 2875, 2804, 1671, 1618, 1573, 1547, 1317, 1223, 1170, 1130, 778, 750 cm⁻¹.

8-Butyl-1-methyl-7-(2-(trifluoromethyl)phenyl)-1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione (46)

¹³C NMR (125 MHz, DMSO-*d*₆): δ = 153.3, 152.9, 151.0, 147.3, 134.2, 132.6, 130.8, 129.3 (q, *J* = 29.2 Hz), 127.0, 126.6 (q, *J* = 5.2 Hz), 125.4 (q, *J* = 1.7 Hz), 123.6 (q, *J* = 273.7 Hz), 106.6, 98.8, 43.2, 30.0, 28.9, 18.8, 13.1; IR (film): $\tilde{\nu}$ = 3169, 3034, 2959, 2873, 2820, 1701, 1671, 1509, 1443, 1309, 1179, 1136, 781 cm⁻¹.

Synthesis of compounds 49 and 50

8-(Butylamino)-7-(2-(2,6-dimethylphenyl)-2-oxoethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (38)

A mixture of 8-bromo-7-(2-(2,6-dimethylphenyl)-2-oxoethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (**29**, 88 mg, 0.22 mmol) and butyl amine (0.088 mL, 0.89 mmol) in EtOH (2 mL) was

heated in a sealed tube at 175 °C for 2 h. The reaction was cooled to room temperature and the solid was filtered off to afford the crude product as a light yellow solid (68 mg, 81% yield). ¹H NMR (500 MHz, DMSO-*d*₆): δ = 10.70 (s, 1H), 7.26 (t, *J* = 7.6 Hz, 1H), 7.11 (d, *J* = 7.6 Hz, 2H), 6.91 (t, *J* = 5.4 Hz, 1H), 5.35 (s, 2H), 3.34 (s, 5H), 2.27 (s, 6H), 1.52 (quint, *J* = 7.3 Hz, 2H), 1.34 (sext, *J* = 7.3 Hz, 2H), 0.90 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆): δ = 202.7, 155.0, 153.2, 150.9, 150.2, 138.2, 133.5, 129.3, 127.7, 102.3, 53.3, 41.9, 31.1, 28.4, 19.3, 18.7, 13.6; IR (film): $\tilde{\nu}$ = 3342, 3152, 2987, 2934, 1673, 1614, 1545, 1439, 1223, 750 cm⁻¹; HRMS (ESI): *m/z*: calcd for C₂₀H₂₅N₅O₃H⁺: 384.2030, found: 384.2032.

8-(Butylamino)-3-methyl-7-(2-(5-methyl-1H-indazol-4-yl)-2-oxoethyl)-1H-purine-2,6(3H,7H)-dione (39)

¹³C NMR (125 MHz, DMSO-*d*₆): δ = 197.2, 154.9, 153.2, 150.9, 150.3, 138.8, 132.6, 129.9, 129.4, 127.3, 120.4, 113.3, 101.7, 53.1, 41.9, 31.2, 28.4, 19.8, 19.3, 13.6; IR (film): $\tilde{\nu}$ = 3325, 3141, 3031, 2933, 2862, 2783, 1685, 1671, 1489, 1443, 1223, 1159, 1107, 921, 819, 748 cm⁻¹.



8-Butyl-7-(2,6-dimethylphenyl)-1-methyl-1H-imidazo[2,1-*f*]purine-2,4(3H,8H)-dione (49)



8-(butylamino)-7-(2-(2,6-dimethylphenyl)-2-oxoethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (**38**, 175 mg, 0.46 mmol) was heated in a sealed tube at 175 °C in CH₂Cl₂ (3 mL) in the presence of BF₃·OEt₂ (2 mL, 16.2 mmol) for 6 h. The reaction was poured in water, extracted with CH₂Cl₂, and the organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. Purification by column chromatography on silica gel (EtOAc/Toluene 1:2) followed by recrystallization in acetone afforded the desired compound as a white solid (43 mg, 26% yield) and ca. 87% purity. ¹H NMR (500 MHz, CDCl₃): δ = 7.88 (s, 1H), 7.32 (t, *J* = 7.6 Hz, 1H), 7.26 (s, 1H), 7.18 (d, *J* = 7.6 Hz, 2H), 3.72 (t, *J* = 7.4 Hz, 2H), 3.60 (s, 3H), 2.15 (s, 6H), 1.65 (quint, *J* = 7.4 Hz, 2H), 1.23 (sext, *J* = 7.4 Hz, 2H), 0.82 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ = 153.6, 153.1, 151.1, 148.1, 139.4, 130.1, 129.4, 127.8, 126.5, 105.7, 99.8, 43.5, 30.9, 29.4, 20.4, 19.6, 13.4; IR (film): $\tilde{\nu}$ = 3152, 3044, 2958, 2871, 2820, 1675, 1607, 1512, 1457, 781 cm⁻¹; HRMS (ESI): *m/z*: calcd for C₂₀H₂₃N₅O₂H⁺: 366.1925, found: 366.1921.



8-Butyl-1-methyl-7-(5-methyl-1H-indazol-4-yl)-1H-imidazo[2,1-*f*]purine-2,4(3H,8H)-dione (50)



^{13}C NMR (125 MHz, DMSO- d_6): δ = 153.3, 152.8, 151.0, 147.6, 138.4, 132.2, 130.5, 128.9, 127.8, 124.3, 117.7, 111.8, 106.2, 99.0, 43.1, 30.0, 28.8, 18.8, 18.6, 12.9; IR (film): $\tilde{\nu}$ = 3356, 3194, 2956, 2925, 2857, 1687, 1607, 1513, 1456, 1054, 754 cm^{-1} .



NMR TRACES






















































































































































HPLC Traces of tested compounds




#	RT [min]	Area	FWHM [min]	Area Frac. %
1	1.05	13780		1.2
2	2.45	1118262	0.04	98.8
n.a.	2.47	n.a.	n.a.	n.a.




#	RT [min]	Area	FWHM [min]	Area Frac. %
1	1.05	13746		1.2
2	2.66	1130637	0.04	98.8
n.a.	2.72	n.a.	n.a.	n.a.




#	RT [min]	Area	FWHM [min]	Area Frac. %
1	1.05	11304	0.02	1.0
2	2.87	1080157	0.04	99.0
n.a.	2.92	n.a.	n.a.	n.a.




#	RT [min]	Area	FWHM [min]	Area Frac. %
1	1.05	10938	0.03	1.1
2	2.49	991323	0.04	97.4
3	2.84	15711		1.5
n.a.	2.53	n.a.	n.a.	n.a.




#	RT [min]	Area	FWHM [min]	Area Frac. %
1	1.05	12056.5		0.9
2	2.33	3207.2		0.3
3	2.55	1258883.7	0.04	98.8
n.a.	2.60	n.a.	n.a.	n.a.




#	RT [min]	Area	FWHM [min]	Area Frac. %
1	1.05	11134.1	0.03	1.1
2	2.25	2524.2		0.2
3	2.30	3449.4		0.3
4	2.43	1020709.6	0.04	98.4
n.a.	2.46	n.a.	n.a.	n.a.




#	RT [min]	Area	FWHM [min]	Area Frac. %
1	1.05	10533		0.8
2	2.48	1257846	0.04	99.2
n.a.	2.51	n.a.	n.a.	n.a.




#	RT [min]	Area	FWHM [min]	Area Frac. %
1	1.05	12380.2		0.9
2	1.31	7299.6		0.5
3	1.74	8465.3		0.6
4	1.88	3174.4		0.2
5	2.00	2067.3		0.1
6	2.11	4854.6		0.3
7	2.23	12131.9		0.9
8	2.44	1338824.7	0.04	96.3
9	2.85	1091.3		0.1
n.a.	2.50	n.a.	n.a.	n.a.



#	RT [min]	Area	FWHM [min]	Area Frac. %
1	1.05	10648.66	0.03	1.0
2	1.30	3513.64		0.3
3	1.58	957.91		0.1
4	1.76	6103.18		0.6
5	2.30	1035999.49	0.04	98.0
n.a.	2.32	n.a.	n.a.	n.a.



#	RT [min]	Area	FWHM [min]	Area Frac. %
1	1.05	12520.3		1.1
2	2.45	17708.0	0.02	1.5
3	2.57	997652.5	0.04	86.7
4	2.76	15065.5		1.3
5	2.92	59780.1	0.04	5.2
6	2.98	12859.2	0.03	1.1
7	3.08	15046.6	0.04	1.3
8	3.28	12579.1	0.04	1.1
9	3.36	7012.8		0.6
n.a.	2.55	n.a.	n.a.	n.a.



#	RT [min]	Area	FWHM [min]	Area Frac. %
1	1.75	447.43		0.2
2	1.82	1343.04		0.5
3	1.99	292278.84	0.03	98.7
4	2.69	2103.76		0.7
n.a.	2.03	n.a.	n.a.	n.a.

- Composite Omit Map of Ligand 3

